Which has stronger valuation and earnings, GHRS or BLTE?

Belite Bio is trading at a lower price-to-earnings ratio than GH Research, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GH Research N/A N/A -$48.26M -$1.00 N/A Belite Bio N/A N/A -$77.61M -$2.73 N/A

Is GHRS or BLTE more profitable?

Belite Bio's return on equity of -11.84% beat GH Research's return on equity. Company Net Margins Return on Equity Return on Assets GH Research N/A -20.86% -20.12% Belite Bio N/A -11.84% -11.62%

Does the media prefer GHRS or BLTE?

In the previous week, Belite Bio had 4 more articles in the media than GH Research. MarketBeat recorded 5 mentions for Belite Bio and 1 mentions for GH Research. GH Research's average media sentiment score of 0.67 beat Belite Bio's score of 0.20 indicating that GH Research is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, LNTH or GHRS?

Lantheus has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.23 $233.56M $4.14 24.12 GH Research N/A N/A -$48.26M -$1.00 N/A

Is LNTH or GHRS more profitable?

Lantheus has a net margin of 17.69% compared to GH Research's net margin of 0.00%. Lantheus' return on equity of 28.10% beat GH Research's return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 17.69% 28.10% 14.35% GH Research N/A -20.86% -20.12%

Does the media favor LNTH or GHRS?

In the previous week, Lantheus had 10 more articles in the media than GH Research. MarketBeat recorded 11 mentions for Lantheus and 1 mentions for GH Research. GH Research's average media sentiment score of 0.67 beat Lantheus' score of 0.23 indicating that GH Research is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 1 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GH Research 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AMRX or GHRS?

In the previous week, Amneal Pharmaceuticals had 1 more articles in the media than GH Research. MarketBeat recorded 2 mentions for Amneal Pharmaceuticals and 1 mentions for GH Research. GH Research's average media sentiment score of 0.67 beat Amneal Pharmaceuticals' score of 0.51 indicating that GH Research is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GH Research 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LQDA or GHRS more profitable?

Liquidia has a net margin of 30.74% compared to GH Research's net margin of 0.00%. Liquidia's return on equity of 149.65% beat GH Research's return on equity. Company Net Margins Return on Equity Return on Assets Liquidia 30.74% 149.65% 36.30% GH Research N/A -20.86% -20.12%

Does the media favor LQDA or GHRS?

In the previous week, Liquidia had 27 more articles in the media than GH Research. MarketBeat recorded 28 mentions for Liquidia and 1 mentions for GH Research. GH Research's average media sentiment score of 0.67 beat Liquidia's score of 0.28 indicating that GH Research is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 7 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral GH Research 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, GHRS or DFTX?

GH Research is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GH Research N/A N/A -$48.26M -$1.00 N/A Definium Therapeutics N/A N/A -$183.79M -$3.43 N/A

Is GHRS or DFTX more profitable?

GH Research's return on equity of -20.86% beat Definium Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets GH Research N/A -20.86% -20.12% Definium Therapeutics N/A -84.01% -63.66%

Does the media favor GHRS or DFTX?

In the previous week, Definium Therapeutics had 19 more articles in the media than GH Research. MarketBeat recorded 20 mentions for Definium Therapeutics and 1 mentions for GH Research. GH Research's average media sentiment score of 0.67 beat Definium Therapeutics' score of 0.32 indicating that GH Research is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Definium Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

GH Research (GHRS) Competitors

$22.94 +0.08 (+0.35%)

Closing price 04:00 PM Eastern

Extended Trading

$22.97 +0.03 (+0.13%)

As of 07:30 PM Eastern

Compare

GHRS vs. BLTE, LNTH, AMRX, LQDA, and DFTX

Should you buy GH Research stock or one of its competitors? GH Research's main competitors and comparable companies include Belite Bio (BLTE), Lantheus (LNTH), Amneal Pharmaceuticals (AMRX), Liquidia (LQDA), and Definium Therapeutics (DFTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does GH Research compare to Belite Bio?

GH Research (NASDAQ:GHRS) and Belite Bio (NASDAQ:BLTE) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

GH Research currently has a consensus price target of $45.00, suggesting a potential upside of 100.36%. Belite Bio has a consensus price target of $218.73, suggesting a potential upside of 34.02%. Given GH Research's stronger consensus rating and higher possible upside, equities analysts plainly believe GH Research is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

GH Research has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, indicating that its stock price is 223% less volatile than the broader market.

In the previous week, Belite Bio had 4 more articles in the media than GH Research. MarketBeat recorded 5 mentions for Belite Bio and 1 mentions for GH Research. GH Research's average media sentiment score of 0.67 beat Belite Bio's score of 0.20 indicating that GH Research is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

56.9% of GH Research shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 41.6% of GH Research shares are held by insiders. Comparatively, 13.3% of Belite Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Belite Bio's return on equity of -11.84% beat GH Research's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-20.86%	-20.12%
Belite Bio	N/A	-11.84%	-11.62%

Belite Bio is trading at a lower price-to-earnings ratio than GH Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

Summary

GH Research beats Belite Bio on 10 of the 13 factors compared between the two stocks.

How does GH Research compare to Lantheus?

Lantheus (NASDAQ:LNTH) and GH Research (NASDAQ:GHRS) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Lantheus has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market. Comparatively, GH Research has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market.

99.1% of Lantheus shares are held by institutional investors. Comparatively, 56.9% of GH Research shares are held by institutional investors. 1.7% of Lantheus shares are held by company insiders. Comparatively, 41.6% of GH Research shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Lantheus has a net margin of 17.69% compared to GH Research's net margin of 0.00%. Lantheus' return on equity of 28.10% beat GH Research's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
GH Research	N/A	-20.86%	-20.12%

Lantheus has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.23	$233.56M	$4.14	24.12
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A

In the previous week, Lantheus had 10 more articles in the media than GH Research. MarketBeat recorded 11 mentions for Lantheus and 1 mentions for GH Research. GH Research's average media sentiment score of 0.67 beat Lantheus' score of 0.23 indicating that GH Research is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	1 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GH Research	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus currently has a consensus target price of $108.11, suggesting a potential upside of 8.28%. GH Research has a consensus target price of $45.00, suggesting a potential upside of 100.36%. Given GH Research's stronger consensus rating and higher probable upside, analysts plainly believe GH Research is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29
GH Research	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Lantheus beats GH Research on 9 of the 15 factors compared between the two stocks.

How does GH Research compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and GH Research (NASDAQ:GHRS) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Amneal Pharmaceuticals has a net margin of 5.05% compared to GH Research's net margin of 0.00%. GH Research's return on equity of -20.86% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
GH Research	N/A	-20.86%	-20.12%

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 56.9% of GH Research shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 41.6% of GH Research shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Amneal Pharmaceuticals has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market. Comparatively, GH Research has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market.

Amneal Pharmaceuticals has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	2.13	$72.06M	$0.49	41.03
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A

In the previous week, Amneal Pharmaceuticals had 1 more articles in the media than GH Research. MarketBeat recorded 2 mentions for Amneal Pharmaceuticals and 1 mentions for GH Research. GH Research's average media sentiment score of 0.67 beat Amneal Pharmaceuticals' score of 0.51 indicating that GH Research is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GH Research	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals presently has a consensus target price of $21.00, indicating a potential upside of 4.45%. GH Research has a consensus target price of $45.00, indicating a potential upside of 100.36%. Given GH Research's higher probable upside, analysts plainly believe GH Research is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
GH Research	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Amneal Pharmaceuticals beats GH Research on 8 of the 15 factors compared between the two stocks.

How does GH Research compare to Liquidia?

Liquidia (NASDAQ:LQDA) and GH Research (NASDAQ:GHRS) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

Liquidia has a net margin of 30.74% compared to GH Research's net margin of 0.00%. Liquidia's return on equity of 149.65% beat GH Research's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
GH Research	N/A	-20.86%	-20.12%

In the previous week, Liquidia had 27 more articles in the media than GH Research. MarketBeat recorded 28 mentions for Liquidia and 1 mentions for GH Research. GH Research's average media sentiment score of 0.67 beat Liquidia's score of 0.28 indicating that GH Research is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	7 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
GH Research	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GH Research has lower revenue, but higher earnings than Liquidia. GH Research is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	15.73	-$68.92M	$1.37	20.30
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A

64.5% of Liquidia shares are owned by institutional investors. Comparatively, 56.9% of GH Research shares are owned by institutional investors. 25.6% of Liquidia shares are owned by company insiders. Comparatively, 41.6% of GH Research shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Liquidia presently has a consensus target price of $85.83, indicating a potential upside of 208.59%. GH Research has a consensus target price of $45.00, indicating a potential upside of 100.36%. Given Liquidia's higher probable upside, equities analysts plainly believe Liquidia is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.25
GH Research	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Liquidia has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, GH Research has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market.

Summary

Liquidia beats GH Research on 10 of the 16 factors compared between the two stocks.

How does GH Research compare to Definium Therapeutics?

GH Research (NASDAQ:GHRS) and Definium Therapeutics (NASDAQ:DFTX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

In the previous week, Definium Therapeutics had 19 more articles in the media than GH Research. MarketBeat recorded 20 mentions for Definium Therapeutics and 1 mentions for GH Research. GH Research's average media sentiment score of 0.67 beat Definium Therapeutics' score of 0.32 indicating that GH Research is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Definium Therapeutics	7 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GH Research's return on equity of -20.86% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-20.86%	-20.12%
Definium Therapeutics	N/A	-84.01%	-63.66%

GH Research has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.19, indicating that its stock price is 119% more volatile than the broader market.

GH Research currently has a consensus price target of $45.00, suggesting a potential upside of 100.36%. Definium Therapeutics has a consensus price target of $64.88, suggesting a potential upside of 73.42%. Given GH Research's higher probable upside, equities analysts plainly believe GH Research is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	3.00

56.9% of GH Research shares are held by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are held by institutional investors. 41.6% of GH Research shares are held by insiders. Comparatively, 2.4% of Definium Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

GH Research is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A

Summary

GH Research beats Definium Therapeutics on 8 of the 14 factors compared between the two stocks.

Get GH Research News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GHRS vs. The Competition

Export

Metric	GH Research	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.57B	$12.27B	$7.14B	$13.10B
Dividend Yield	N/A	2.64%	2.54%	16.77%
P/E Ratio	-22.94	794.62	273.67	26.04
Price / Sales	N/A	757.46	612.51	90.64
Price / Cash	N/A	82.26	77.60	51.75
Price / Book	5.09	10.46	10.92	6.30
Net Income	-$48.26M	$2.83B	$3.50B	$361.43M
7 Day Performance	-3.78%	-1.65%	-2.11%	-1.67%
1 Month Performance	-18.28%	-5.77%	-6.34%	-3.94%
1 Year Performance	71.96%	-3.80%	8.81%	2.77%

GH Research Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GHRS GH Research	3.0291 of 5 stars	$22.94 +0.3%	$45.00 +96.2%	+68.5%	$1.57B	N/A	N/A	73
BLTE Belite Bio	3.3351 of 5 stars	$167.06 +0.7%	$218.73 +30.9%	+121.7%	$6.73B	N/A	N/A	41
LNTH Lantheus	3.2165 of 5 stars	$99.57 -0.2%	$108.11 +8.6%	+93.0%	$6.50B	$1.54B	24.06	1,193
AMRX Amneal Pharmaceuticals	3.1145 of 5 stars	$20.13 -1.8%	$21.00 +4.3%	+93.4%	$6.43B	$3.02B	41.09	8,500	Analyst Forecast
LQDA Liquidia	4.1057 of 5 stars	$70.69 -4.0%	$98.08 +38.8%	+26.9%	$6.32B	$158.32M	51.57	216	Trending News Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GHRS) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GH Research (GHRS) Competitors

GHRS vs. BLTE, LNTH, AMRX, LQDA, and DFTX

How does GH Research compare to Belite Bio?

Summary

How does GH Research compare to Lantheus?

Summary

How does GH Research compare to Amneal Pharmaceuticals?

Summary

How does GH Research compare to Liquidia?

Summary

How does GH Research compare to Definium Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHRS vs. The Competition

GH Research Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GH Research (GHRS) Competitors

GHRS vs. BLTE, LNTH, AMRX, LQDA, and DFTX

How does GH Research compare to Belite Bio?

Do analysts rate GHRS or BLTE?

Which has more volatility & risk, GHRS or BLTE?

Does the media prefer GHRS or BLTE?

Do insiders and institutionals hold more shares of GHRS or BLTE?

Is GHRS or BLTE more profitable?

Which has stronger valuation and earnings, GHRS or BLTE?

Summary

How does GH Research compare to Lantheus?

Which has more volatility and risk, LNTH or GHRS?

Do institutionals & insiders hold more shares of LNTH or GHRS?

Is LNTH or GHRS more profitable?

Which has higher earnings & valuation, LNTH or GHRS?

Does the media favor LNTH or GHRS?

Do analysts prefer LNTH or GHRS?

Summary

How does GH Research compare to Amneal Pharmaceuticals?

Is AMRX or GHRS more profitable?

Do institutionals and insiders believe in AMRX or GHRS?

Which has more risk & volatility, AMRX or GHRS?

Which has higher earnings and valuation, AMRX or GHRS?

Does the media favor AMRX or GHRS?

Do analysts rate AMRX or GHRS?

Summary

How does GH Research compare to Liquidia?

Is LQDA or GHRS more profitable?

Does the media favor LQDA or GHRS?

Which has stronger valuation and earnings, LQDA or GHRS?

Do institutionals & insiders have more ownership in LQDA or GHRS?

Do analysts rate LQDA or GHRS?

Which has more volatility & risk, LQDA or GHRS?

Summary

How does GH Research compare to Definium Therapeutics?

Does the media favor GHRS or DFTX?

Is GHRS or DFTX more profitable?

Which has more risk & volatility, GHRS or DFTX?

Do analysts rate GHRS or DFTX?

Do institutionals and insiders believe in GHRS or DFTX?

Which has higher earnings and valuation, GHRS or DFTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHRS vs. The Competition

GH Research Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools